Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma

It is unknown whether tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) can be discontinued in patients in whom EGFR-mutated lung cancer has well stabilised. We present a case of a 73-year-old Japanese woman with no history of smoking. Right pulmonary lower lobectomy, lymp...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamanaka, Yumie, Seki, Yoshitaka, Ishikawa, Takeo, Kuwano, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357919/
https://www.ncbi.nlm.nih.gov/pubmed/30709831
http://dx.doi.org/10.1136/bcr-2018-227383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357919/
https://www.ncbi.nlm.nih.gov/pubmed/30709831
http://dx.doi.org/10.1136/bcr-2018-227383

Ejemplares similares